| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/25/2004 | EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
| 02/25/2004 | EP1390055A2 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 02/25/2004 | EP1390054A2 Mu-conopeptides |
| 02/25/2004 | EP1390037A1 Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 02/25/2004 | EP1390034A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| 02/25/2004 | EP1390025A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 02/25/2004 | EP1390023A2 Pharmaceutical salts |
| 02/25/2004 | EP1390022A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno 2,3-d]pyrimidine for the treatment of pain |
| 02/25/2004 | EP1390021A1 Delivery of compounds for the treatment of migraine through an inhalation route |
| 02/25/2004 | EP1390018A1 A pharmaceutical tablet having a high api content |
| 02/25/2004 | EP1390011A2 Control of compactability through crystallization |
| 02/25/2004 | EP1389970A2 Compositions and methods of double-targeting virus infections and cancer cells |
| 02/25/2004 | EP1301503B1 Coumarin derivatives with comt inhibiting activity |
| 02/25/2004 | EP1263756B1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 02/25/2004 | EP1239879B1 Formulations of adenosine a1 agonists and cox2-inhibitors |
| 02/25/2004 | EP1239878B1 Formulations of adenosine a1 agonists and 5ht1 agonists |
| 02/25/2004 | EP1210326B1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/25/2004 | EP1200409B1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/25/2004 | EP1165064B1 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 02/25/2004 | EP1140931B1 5ht1 antagonists for antidepressant therapy |
| 02/25/2004 | EP1087934B1 Aminocyclohexyl ether compounds and uses thereof |
| 02/25/2004 | EP1042296B1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/25/2004 | EP1037612B1 Pharmaceutical compositions containing micronized bicyclic drugs |
| 02/25/2004 | EP1032402B1 Use of citicoline for the treatment of multiple sclerosis (MS) |
| 02/25/2004 | EP0946181B1 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications |
| 02/25/2004 | EP0790059B1 Means for treating auto-immune diseases |
| 02/25/2004 | EP0751957B1 Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases |
| 02/25/2004 | CN1478146A Calcium binding proteins |
| 02/25/2004 | CN1478098A Modulation of IL-2-and IL-15-mediated T cell responses |
| 02/25/2004 | CN1478092A Benzoxazinone derivatives, their preparation and use |
| 02/25/2004 | CN1478089A Substituted derivatives of aminofuran-2-Y1-acetic acid and aminothien-2-Y1-acetic acid and use thereof for treating migraines and pain |
| 02/25/2004 | CN1478088A Benzothiophene derivative compounds, process of preparation and use thereof |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478084A Compounds useful in treatment of inflammatory diseases |
| 02/25/2004 | CN1478080A Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/25/2004 | CN1478067A O-substituted 6-methyl-tramadol derivatives |
| 02/25/2004 | CN1477976A Combination of GABA agonists and aldose reductase inhibitors |
| 02/25/2004 | CN1477975A Combination of GABA agonists and sorbitol dehydrogenase inhibitors |
| 02/25/2004 | CN1477969A Chemokine mutants in treatment of multiple sclerosis |
| 02/25/2004 | CN1477968A Methods for treating rheumatic diseases using soluble CTLA4 molecule |
| 02/25/2004 | CN1477967A Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 02/25/2004 | CN1477961A Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders |
| 02/25/2004 | CN1477960A EPA receptor inhibitors to treat rheumatoid arthritis |
| 02/25/2004 | CN1477958A Composition and method |
| 02/25/2004 | CN1477957A Tanshinone compound containing dihydrofuran ring structure for curing hyperammonemia and hepatic encephalopathy |
| 02/25/2004 | CN1477956A Crytotanshinone for preventing and delaying early senile dementia |
| 02/25/2004 | CN1477955A Parenteral dosage forms comprising suspension of tramadol salt and diclofenac salt |
| 02/25/2004 | CN1476888A Powder preparation for dispelling effects of liquor and its preparation method |
| 02/25/2004 | CN1476844A Preparation method of medicine powder for curing epilepsy |
| 02/25/2004 | CN1476834A Metaduocine freeze-dried powder injection preparation and its preparation method |
| 02/25/2004 | CN1139589C Tetrahydroimidazo [2,1-a] isoquinoline derivatives |
| 02/25/2004 | CN1139588C Novel fluorinated imidazoline benzodioxane, preparation and therapeutic use thereof |
| 02/25/2004 | CN1139584C Heterocyclic compounds, method for preparing and medicine composition containing same |
| 02/25/2004 | CN1139580C Substituted benzylamines and their use for treatment of depression |
| 02/25/2004 | CN1139579C Isoxazolecarboxamide derivatives |
| 02/25/2004 | CN1139572C NMDA (N-methl-D-aspartate) antagonists |
| 02/25/2004 | CN1139570C Inhibition of matrix metalloproteases by acetylene-containing compound |
| 02/25/2004 | CN1139398C Chinese medicine for treating diabetic neural lesion |
| 02/25/2004 | CN1139391C Medicine for dropping off drug |
| 02/24/2004 | US6696567 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/24/2004 | US6696566 Selective p38 kinase inhibitors relative to cyclin-dependent kinases and tyrosine kinases |
| 02/24/2004 | US6696495 Treatment of disorders secondary to organic impairments |
| 02/24/2004 | US6696470 Pyridylthiophene compounds |
| 02/24/2004 | US6696464 Triazolo-pyridines anti-inflammatory compounds |
| 02/24/2004 | US6696458 Having x-ray powder diffraction pattern with lines at degrees 2 theta values 6.7, 12.5, 14.0 and 23.9 for cu k alpha radiation of wavelength 1.5406 angstrom |
| 02/24/2004 | US6696457 Morphinoid compounds |
| 02/24/2004 | US6696452 Glycogen synthase kinase-3 and aurora-2 a serine/threonine protein kinase inhibitors; antidiabetic and anticancer agents and alzheimer's disease treatments |
| 02/24/2004 | US6696450 Serotonergic agents with long-acting in vivo effects |
| 02/24/2004 | US6696449 Control degradation of conencting tissue; cardiovascular disorders |
| 02/24/2004 | US6696447 Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain |
| 02/24/2004 | US6696446 Benzoylpyridazines, their preparation and use |
| 02/24/2004 | US6696445 Neuropeptide y receptor antagonists comprising heterocyclic nitrogen compounds and/or prodrugs used for prophylaxis of eating and cardiovascular disorders |
| 02/24/2004 | US6696444 Neurotransmitter antagonists comprising compounds such as 4,2'-difluoro-5'-(3-(1-fluoro-1-methylethyl)imidazo(1,2-b)(1,2 ,4) triazin-7-yl)biphenyl-2-carbonitrile, administered for the prophylaxis of headaches or as anticonvulsants |
| 02/24/2004 | US6696443 Piperidine/piperazine-type inhibitors of p38 kinase |
| 02/24/2004 | US6696442 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| 02/24/2004 | US6696439 Heterocyclic imines such as 2-methyl-3-(2-(n',n'-diethylamino) ethyl)-5-(4-propanesulfonylbenzamide)furo(3,2-b)pyridine, hydrochloride, used as serotonin receptor antagonists for prophylaxis of headaches |
| 02/24/2004 | US6696437 Polymerase inhibitors comprising heterocyclic amides such as 2-pyridin-2-ylbenzimidazole-4-carboxamide, used for prophylaxis of neurodegenerative disorders, damage to hearts or brains, and as anticarcinogenic agents |
| 02/24/2004 | US6696408 Administering glycosylated polypeptides as antiepileptics and anticonvulsants or for prophylaxis of psychological disorders |
| 02/24/2004 | US6696303 Inhibition of amyloid protein bnding to neuronal receptor; obtain cell, incubate with modulator, monitor amyloid protein activity |
| 02/24/2004 | US6696273 FEBP1 Protein: vector, host cells and method for making FEBP1 protein |
| 02/24/2004 | US6696091 Pharmaceutical composition of topiramate |
| 02/24/2004 | US6696088 Useful for decreasing the potential for abuse of the opioid agonist contained therein; for use in therapy of pain |
| 02/24/2004 | US6696066 Opioid agonist/antagonist combinations |
| 02/24/2004 | US6696039 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 02/24/2004 | CA2279186C Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| 02/24/2004 | CA2114542C Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists |
| 02/23/2004 | CA2399630A1 Scyphostatin analogues as smase inhibitors |
| 02/23/2004 | CA2399532A1 Controlled release formulation of divalproex sodium |
| 02/21/2004 | CA2437664A1 Anti-aging/menopause symptoms relief using ganoderma lucidum spores |
| 02/19/2004 | WO2004015140A1 Methods for the treatment of dementia based on apo e genotype |
| 02/19/2004 | WO2004015109A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 02/19/2004 | WO2004015106A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | WO2004014953A2 Anti-myelin associated glycoprotein (mag) antibodies |
| 02/19/2004 | WO2004014927A1 Mitochondrially targeted antioxidants |
| 02/19/2004 | WO2004014922A1 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014913A2 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014910A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | WO2004014905A1 Substituted benzimidazole compounds |